Confidence interval criteria for assessment of dose proportionality. - Wikidata - awgldk - TriplyDB

Confidence interval criteria for assessment of dose proportionality.

Confidence interval criteria for assessment of dose proportionality.

http://www.wikidata.org/entity/Q52069368

about

Pharmacokinetics and pharmacodynamics of LC15-0444, a novel dipeptidyl peptidase IV inhibitor, after multiple dosing in healthy volunteers The pharmacokinetics, CNS pharmacodynamics and adverse event profile of brivaracetam after multiple increasing oral doses in healthy men Lucerastat, an iminosugar with potential as substrate reduction therapy for glycolipid storage disorders: safety, tolerability, and pharmacokinetics in healthy subjects Pharmacokinetics of Active Components of Yokukansan, a Traditional Japanese Herbal Medicine after a Single Oral Administration to Healthy Japanese Volunteers: A Cross-Over, Randomized Study Safety and feasibility of long-term intravenous sodium nitrite infusion in healthy volunteers.A phase I study of tasisulam sodium (LY573636 sodium), a novel anticancer compound, administered as a 24-h continuous infusion in patients with advanced solid tumors.Phase I Study of Veliparib (ABT-888) Combined with Cisplatin and Vinorelbine in Advanced Triple-Negative Breast Cancer and/or BRCA Mutation-Associated Breast Cancer Pharmacokinetic evaluation of the anticancer prodrug simmitecan in different experimental animals.Multiple-dose safety, tolerability, and pharmacokinetics of oral nemonoxacin (TG-873870) in healthy volunteers.Pharmacokinetics and safety of calcium L-threonate in healthy volunteers after single and multiple oral administrations Pharmacokinetics and pharmacodynamics of single and multiple doses of prasugrel in healthy native Chinese subjects.Phase I trial of a novel anti-GD2 monoclonal antibody, Hu14.18K322A, designed to decrease toxicity in children with refractory or recurrent neuroblastoma.A first-in-human, double-blind, placebo-controlled, randomized, dose escalation study of DWP05195, a novel TRPV1 antagonist, in healthy volunteers Safety/tolerability of the anti-semaphorin 4D Antibody VX15/2503 in a randomized phase 1 trial.A Phase I Study of Oral Paclitaxel with a Novel P-Glycoprotein Inhibitor, HM30181A, in Patients with Advanced Solid Cancer Single- and multiple-dose pharmacokinetics of etoricoxib, a selective inhibitor of cyclooxygenase-2, in man.Safety, tolerability and pharmacokinetics of single and multiple doses of a novel sigma-1 receptor antagonist in three randomized phase I studies.Safety, tolerability, and pharmacokinetic evaluation of single- and multiple-ascending doses of a novel kappa opioid receptor antagonist LY2456302 and drug interaction with ethanol in healthy subjects.Pharmacokinetics and safety profile of ispronicline (TC-1734), a new brain nicotinic receptor partial agonist, in young healthy male volunteers.Use of microdosing and accelerator mass spectrometry to evaluate the pharmacokinetic linearity of a novel tricyclic GyrB/ParE inhibitor in rats USL255 extended-release topiramate: dose-proportional pharmacokinetics and tolerability in healthy volunteers.Effects of the cholesteryl ester transfer protein inhibitor evacetrapib on lipoproteins, apolipoproteins and 24-h ambulatory blood pressure in healthy adults First-in-humans study of the safety, tolerability, and pharmacokinetics of ACT-451840, a new chemical entity with antimalarial activity.Dose selection method for pharmacokinetic study in hemodialysis patients using a subpharmacological dose: oseltamivir as a model drug.Single and multiple dose pharmacokinetics and tolerability of HX-1171, a novel antioxidant, in healthy volunteers Safety, pharmacokinetics, and pharmacodynamics of TV-1380, a novel mutated butyrylcholinesterase treatment for cocaine addiction, after single and multiple intramuscular injections in healthy subjects.A phase I study of tasisulam sodium (LY573636 sodium), a novel anticancer compound in patients with refractory solid tumors Determination of salvianolic acid C in rat plasma using liquid chromatography-mass spectrometry and its application to pharmacokinetic study.Pharmacokinetic Profiles of Active Ingredients and Its Metabolites Derived from Rikkunshito, a Ghrelin Enhancer, in Healthy Japanese Volunteers: A Cross-Over, Randomized Study.Intravenous Pharmacokinetics, Local Tolerability, and Hemolysis of an SBE7-β-Cyclodextrin Formulation of the Neurokinin-1 Receptor Antagonist Vestipitant.Dose proportionality and pharmacokinetics of carvedilol sustained-release formulation: a single dose-ascending 10-sequence incomplete block study.Tadalafil pharmacokinetics in healthy subjects Daptomycin versus vancomycin in a methicillin-resistant Staphylococcus aureus endophthalmitis rabbit model: bactericidal effect, safety, and ocular pharmacokinetics.Pharmacokinetics, pharmacodynamics, and tolerability of LC350189, a novel xanthine oxidase inhibitor, in healthy subjects Volociximab, a chimeric monoclonal antibody that specifically binds alpha5beta1 integrin: a phase I, pharmacokinetic, and biological correlative study.A rapid and efficient analytical method for the quantification of a novel anticholinergic compound, R-phencynonate, by stable isotope-dilution LC-MS/MS and its application to bioavailability and dose proportionality studies.Pharmacokinetics and tissue distribution of coptisine in rats after oral administration by liquid chromatography-mass spectrometry.Pharmacokinetic study of salvianolic acid D after oral and intravenous administration in rats.Clinical Pharmacokinetics of IPX066: Evaluation of Dose Proportionality and Effect of Food in Healthy Volunteers.Pharmacokinetic study of gallocatechin-7-gallate from Pithecellobium clypearia Benth. in rats.

P2860

Q24658008-38C57A32-AFA4-4BEC-A937-075981617305 Q28272717-E1D33348-0413-4E4B-A642-D74FF213D39B Q28468569-1672B248-37A7-469B-B01F-4CD16AE04F10 Q28546355-46164ED6-16D3-4169-A933-366B14A37C58 Q28743602-BB3D1306-01D0-4A4A-A891-7924DAD0B602 Q33404760-2AFC3A0F-BED5-4B57-B77D-E1D1A4509308 Q33429434-E7B6D38C-AECA-4612-BBC5-52625C1EE1CA Q33551915-07428630-AFBF-4F5E-AC41-C6FB130B911C Q33559026-F921CA27-33D5-4D5F-99BB-71F0779CB1D9 Q33566800-1D8EE99B-497D-4A55-9A52-7209D0E7921C Q33571446-E432609D-37E1-479B-A2AD-355FB731F336 Q33597441-9D001B1C-0065-4E63-A2A7-BD1E79DB4E9A Q33621161-A0FEC1E8-A16F-4F60-9EFC-0C53A7A4F114 Q33808273-5CFE25E6-AC81-4563-8AA8-0FC412A4E0C9 Q34043403-3443057E-9967-4173-86BB-79DC2FD016CC Q34183755-19004AF9-6A6B-4A88-B207-6786E6673A3A Q34275887-E953B740-F4E8-4A55-B4E2-40BBF716C3EC Q34409641-B9B80C0B-C7B7-4BBD-A1D5-A47B34BE06A8 Q34543205-6AF4DF94-09C7-4892-8E57-975A67CEDE8F Q34596727-FB1AF488-44F1-4808-8FAB-3D57EF3B5A20 Q34822816-45554727-99D0-4E41-B736-206CF7EB7854 Q34823459-78576F45-37EC-46A0-A5B6-395D6F7AF38E Q35105980-5AD73733-1426-416B-8365-DB250AD62392 Q35122440-E8AF812A-7236-4963-B480-3B06A074D786 Q35223225-C1BAE67A-8C87-465D-B040-5F6505776329 Q35468865-4EE95B1A-49E7-495A-A5F3-672D78DD081D Q35549459-E2F12305-D69D-4B1C-9ABB-63F624B6CA1A Q35691253-B8783D78-09DA-443C-A816-70152AF5F42E Q35694926-4242AD7A-45B5-4B2E-B7D3-2CDE549561B7 Q35741941-38BF6AD8-C0FC-4FB1-BF52-A0328BD205D7 Q35746830-C3A39678-4C14-4CF0-8A83-16A1EC8E2737 Q35827477-039B5A1E-EF5C-468C-BEA2-93283A0FC8B8 Q35941248-BED0E105-29AB-4ACE-A29D-46A727048CE6 Q36029222-02EED1AB-76C7-40F4-952A-A4DE46D9AFB5 Q36087887-C5DC4306-020F-44F2-8F64-8B2B9DF22AC6 Q36176850-30F224AE-D092-4132-BF39-732E2528A661 Q36221400-71874E9C-163E-4B0D-BF58-CA67C2DD7EF4 Q36238082-1651F40C-B2EB-4C23-884D-948743FBBF3B Q36467274-F5F2AE1F-C5FA-4404-A1C3-F3818DA8DB4E Q36495588-4D6834C8-B998-4776-831D-097FE39A7C80

P2860

Confidence interval criteria for assessment of dose proportionality.

http://www.wikidata.org/entity/Q52069368

description

2000 nî lūn-bûn

@nan

2000年の論文

@ja

2000年学术文章

@wuu

2000年学术文章

@zh

2000年学术文章

@zh-cn

2000年学术文章

@zh-hans

2000年学术文章

@zh-my

2000年学术文章

@zh-sg

2000年學術文章

@yue

2000年學術文章

@zh-hant

name

Confidence interval criteria for assessment of dose proportionality.

@en

Confidence interval criteria for assessment of dose proportionality.

@nl

type

label

Confidence interval criteria for assessment of dose proportionality.

@en

Confidence interval criteria for assessment of dose proportionality.

@nl

prefLabel

Confidence interval criteria for assessment of dose proportionality.

@en

Confidence interval criteria for assessment of dose proportionality.

@nl

P1433

Q52069368-A573B049-0D4E-49BF-9E34-DC5036152E37

P1476

Q52069368-F058D852-8CAD-49B5-8A76-AB54489FA99D

P2093

Q52069368-0A62FBE0-348E-4902-90E3-CD56619C52B6

Q52069368-412DD5AB-8E51-4B66-A649-8BDF6EA00E8F

Q52069368-742D9F21-905D-40F1-99F8-926236DDE503

Q52069368-751B65A1-16E3-48AB-9E4F-F75A5FCFF95D

Q52069368-859D857E-2DF6-46A2-9AEA-E1B591759608

Q52069368-8F6FEC35-EC44-444A-9AA1-0D8F0FEF970E

Q52069368-F337048B-8F7C-4FD7-8AB1-A857AEF3AB84

P304

Q52069368-2E4982FE-6C9B-4028-A994-1C49F2FA0E61

P31

Q52069368-060CCD04-FC9F-42E0-9831-C5D73EAAF470

P356

Q52069368-42E32C11-12D2-4F01-B1FA-EF7886BB8531

P433

Q52069368-E97243F2-3173-4B21-9F46-C4628666E1EE

P478

Q52069368-E76FDC92-DF8C-4452-B950-DFB105166272

P577

Q52069368-3180034B-2FBA-4F23-A659-EB40D0650282

P5875

Q52069368-2D2DECDB-612D-45C2-921E-C33A468F3711

P698

Q52069368-39B18C17-FE7A-4040-90CB-6F7E61CD69ED

P356

A:1026451721686

P1433

Pharmaceutical Research

P1476

Confidence interval criteria for assessment of dose proportionality.

@en

P2093

B P Smith

http://www.w3.org/2001/XMLSchema#string

F R Vandenhende

http://www.w3.org/2001/XMLSchema#string

J T Callaghan

http://www.w3.org/2001/XMLSchema#string

K A DeSante

http://www.w3.org/2001/XMLSchema#string

N A Farid

http://www.w3.org/2001/XMLSchema#string

P A Welch

http://www.w3.org/2001/XMLSchema#string

S T Forgue

http://www.w3.org/2001/XMLSchema#string

P304

1278-1283

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1023/A:1026451721686

http://www.w3.org/2001/XMLSchema#string

P433

10

http://www.w3.org/2001/XMLSchema#string

P478

17

http://www.w3.org/2001/XMLSchema#string

P577

2000-10-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

226019208

http://www.w3.org/2001/XMLSchema#string

P698

11145235

http://www.w3.org/2001/XMLSchema#string